Intellia Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology. Its programs focus on in vivo editing delivered systemically, aiming to treat genetic diseases such as transthyretin amyloidosis and hereditary angioedema with one-time or durable therapies. The company is a clinical-stage biotech whose platform is designed to permanently modify disease-causing genes inside the body rather than only editing cells outside the patient.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 16.6 | — | -114.3 | — |
| Q2 2025 | 14.2 | — | -101.3 | — |
| Q3 2025 | 13.8 | — | -101.3 | — |
| Q4 2025 | 23 | — | -95.8 | — |
| Q1 2026 | 15.1 | -9.5% | -96.2 | — |
| Q2 2026 | 7.7 | -46.2% | -106.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hycroft Mining Holding Corporation (HYMC), Weibo Corporation (WB), Opera Limited (OPRA), Gentherm Incorporated (THRM), Liberty Latin America Ltd. (LILA), Anterix Inc. (ATEX)